CL2021001096A1 - Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) - Google Patents

Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Info

Publication number
CL2021001096A1
CL2021001096A1 CL2021001096A CL2021001096A CL2021001096A1 CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1 CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1
Authority
CL
Chile
Prior art keywords
myelodysplastic syndrome
methods
mds
subject
divisional application
Prior art date
Application number
CL2021001096A
Other languages
English (en)
Inventor
Aleksandra Rizo
Jacqueline Cirillo Bussolari
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2021001096A1 publication Critical patent/CL2021001096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación proporciona métodos para tratar un síndrome mielodisplásico (MDS) en un sujeto que no ha recibido tratamiento con un agente seleccionado de un agente de hipometilación (HMA) y lenalidomida, o ambos. El método incluye administrar al sujeto una cantidad eficaz de un inhibidor de la telomerasa, como por ejemplo, el imetelstat o el sodio de imetelstat. En algunos casos, el sujeto tratado se clasifica como con MDS de riesgo bajo/intermedio-1 de IPSS y/o que tiene MDS recidivante/resistente a agente estimulante de la eritropoyesis (ESA).
CL2021001096A 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) CL2021001096A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US201862685542P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
CL2021001096A1 true CL2021001096A1 (es) 2021-11-12

Family

ID=63209674

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.
CL2021001096A CL2021001096A1 (es) 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.

Country Status (16)

Country Link
US (1) US20190030064A1 (es)
EP (1) EP3658156A1 (es)
JP (3) JP7316261B2 (es)
KR (1) KR20200033269A (es)
CN (1) CN110944646A (es)
AU (1) AU2018307983A1 (es)
BR (1) BR112020001749A2 (es)
CA (1) CA3069010A1 (es)
CL (2) CL2020000196A1 (es)
IL (1) IL272163A (es)
MA (1) MA49688A (es)
NZ (1) NZ760873A (es)
SG (1) SG11201913984RA (es)
TW (1) TW201919705A (es)
UA (1) UA127701C2 (es)
WO (1) WO2019023667A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20210110303A (ko) * 2018-11-29 2021-09-07 제론 코포레이션 골수이형성 증후군을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667522B1 (en) 2003-09-09 2018-01-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PL2928477T3 (pl) * 2012-12-07 2020-03-31 Geron Corporation Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
PL3065828T3 (pl) * 2013-11-06 2019-06-28 Mayo Foundation For Medical Education And Research Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych

Also Published As

Publication number Publication date
CN110944646A (zh) 2020-03-31
AU2018307983A1 (en) 2020-02-13
TW201919705A (zh) 2019-06-01
SG11201913984RA (en) 2020-02-27
US20190030064A1 (en) 2019-01-31
EP3658156A1 (en) 2020-06-03
CA3069010A1 (en) 2019-01-31
CL2020000196A1 (es) 2020-11-20
BR112020001749A2 (pt) 2020-07-21
JP7316261B2 (ja) 2023-07-27
WO2019023667A1 (en) 2019-01-31
JP2020528915A (ja) 2020-10-01
MA49688A (fr) 2020-06-03
IL272163A (en) 2020-03-31
KR20200033269A (ko) 2020-03-27
JP2024015000A (ja) 2024-02-01
UA127701C2 (uk) 2023-12-06
JP2023009229A (ja) 2023-01-19
NZ760873A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CO2021007006A2 (es) Moduladores de la expresión de irf5
PE20210109A1 (es) Moduladores de la expresion de irf4
UY38720A (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112022010750A2 (pt) Método para tratar câncer usando célula adjuvante artificial (aavc)
UY38472A (es) Moduladores de la expresión de foxp3
CL2020001851A1 (es) Moduladores de la expresión dnm2
CL2021001386A1 (es) Métodos de tratamiento del síndrome mielodisplásico
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical
AR112288A1 (es) Métodos para tratar el síndrome mielodisplásico
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol